Clinical trial NCT06671483: A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
Official title: A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naïve to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Psoriatic Arthritis
Keywords: Drug Therapy
Latitude Research Program
Latitude PsA
Latitude PsA-3001
Lead sponsor: Takeda
Sponsor class: INDUSTRY
First posted: 2024-11-04
Enrollment: 1088
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO).

The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs.

The participants will be treated with either zasocitinib, active comparator, or placebo. Participants will be in the study for up to 60 weeks.


Eligibility criteria: Inclusion Criteria:

Age:

1. The participant is aged 18 years or older at the time of signing the informed consent form (ICF). In South Korea, the age requirement for adult participants is \>=19 years of age.

   Disease Characteristics:
2. The participant has had signs and symptoms consistent with PsA for at least 3 months.
3. The participant meets the Classification Criteria for Psoriatic Arthritis (CASPAR criteria).
4. The participant has active arthritis as shown by a minimum of \>=3 tender joints in TJC68 and \>=3 swollen joints in SJC66 at the screening and baseline (Day 1) visits.
5. The participant has at least 1 active lesion of plaque PsO \>=2 cm in diameter, or any nail or nail bed changes characteristic of PsO.

   Medications for PsA:
6. The participant has had at least one of the following:

   1. Inadequate response to a nonsteroidal anti-inflammatory drug (NSAID), OR
   2. Inadequate response to a conventional synthetic disease-modifying antirheumatic drug (csDMARD).

Exclusion Criteria:

PsA and PsO:

1. The participant has other disease(s) that might confound the evaluations of benefit of zasocitinib therapy, including but not limited to rheumatoid arthritis, axial spondyloarthritis, systemic lupus erythematosus, Lyme disease, gout, or fibromyalgia.
2. The participant has a concomitant comorbid skin condition that, in the opinion of the investigator, would interfere with the study assessments, such as evidence of non-plaque PsO (erythrodermic, pustular, predominately guttate PsO, inverse, or drug-induced PsO).

Primary outcomes:
measure: Percentage of Participants Achieving American College of Rheumatology 20 (ACR20) Response at Week 16 for Zasocitinib Dose A and B Compared to Placebo
timeFrame: At Week 16
Secondary outcomes:
measure: Percentage of Participants Achieving Minimal Disease Activity (MDA) at Week 16 for Zasocitinib Dose A and B Compared to Placebo
timeFrame: At Week 16
measure: Percentage of Participants Achieving PASI-75 Response (in Participants With a Baseline >=3% BSA) at Week 16 for Zasocitinib Dose A and B Compared to Placebo
timeFrame: Baseline, at Week 16
measure: Percentage of Participants Achieving ACR50 Response at Week 16 for Zasocitinib Dose A and B Compared to Placebo
timeFrame: At Week 16
measure: Change From Baseline in the HAQ-DI Score at Week 16 for Zasocitinib Dose A and B Compared to Placebo
timeFrame: Baseline, at Week 16
measure: Percentage of Participants Achieving ACR70 Response at Week 16 for Zasocitinib Dose A and B Compared to Placebo
timeFrame: At Week 16
measure: Change From Baseline in the Short Form-36 Health Survey Version 2.0 (SF-36 v2.0) Physical Component Summary (PCS) Score at Week 16 for Zasocitinib Dose A Compared to Placebo
timeFrame: Baseline, at Week 16
measure: Change From Baseline in the Functional Assessment of Chronic Illness Therapy (FACIT)- Fatigue Score at Week 16 for Zasocitinib Dose A Compared to Placebo
timeFrame: Baseline, at Week 16
measure: Percentage of Participants Achieving ACR20 Response at Week 16 for Zasocitinib Dose A and B Compared to Active Comparator
timeFrame: At Week 16
measure: Percentage of Participants Achieving PASI-75 Response (in Participants With a Baseline >=3% BSA) at Week 16 for Zasocitinib Dose A compared to Active Comparator
timeFrame: Baseline, at Week 16
measure: Percentage of Participants Achieving LEI =0 (in Participants With a Baseline LEI >=1) at Week 16 for Zasocitinib Dose A and B Compared to Placebo
timeFrame: Baseline, at Week 16
measure: Change From Baseline in Individual Components of ACR Response at Week 16 for Zasocitinib Dose A and B Compared to Placebo
timeFrame: Baseline, at Week 16
measure: Percentage of Participants Achieving Leeds Dactylitis Index (LDI) =0 (in Participants With a Baseline LDI >=1) at Week 16 for Zasocitinib Dose A and B Compared to Placebo
timeFrame: Baseline, at Week 16
measure: Percentage of Participants Achieving PASI-75 Response (in Participants With a Baseline >=3% BSA) at Week 8 for Zasocitinib Dose A and B Compared to Placebo
timeFrame: Baseline, at Week 8
measure: Percentage of Participants Achieving PASI-90 Response (in Participants With a Baseline >=3% BSA) at Week 16 for Zasocitinib Dose A and B Compared to Placebo
timeFrame: Baseline, at Week 16
measure: Percentage of Participants Achieving PASI-100 Response (in Participants With a Baseline >=3% BSA) at Week 16 for Zasocitinib Dose A and B Compared to Placebo
timeFrame: Baseline, at Week 16
measure: Percentage of Participants Achieving ACR50 and PASI-100 Response (in Participants With a Baseline >=3% BSA) Simultaneously at Week 16 for Zasocitinib Dose A and B Compared to Placebo
timeFrame: Baseline, at Week 16
measure: Percentage of Participants Achieving sPGA Response of Clear (0) or Almost Clear (1) With >=2-Point Decrease From Baseline (in Participants With a Baseline sPGA >=2) at Week 16 for Zasocitinib Dose A and B Compared to Placebo
timeFrame: Baseline, at Week 16
measure: Percentage of Responders Achieving Minimal Clinically Important Differences (Reduction of >=0.35 From Baseline) in HAQ-DI Score From Baseline at Week 16 for Zasocitinib Dose A and B Compared to Placebo
timeFrame: Baseline, at Week 16
measure: Change From Baseline in the SF-36 v2.0 Mental Component Summary (MCS) Score at Week 16 for Zasocitinib Dose A and B Compared to Placebo
timeFrame: Baseline, at Week 16
measure: Change From Baseline in Psoriatic Arthritis Impact of Disease-12 Items (PsAID-12) Total Score at Week 16 for Zasocitinib Dose A and B Compared to Placebo
timeFrame: Baseline, at Week 16
measure: Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) Score at Week 16 for Zasocitinib Dose A and B Compared to Placebo
timeFrame: Baseline, at Week 16
measure: Change From Baseline in Disease Activity Score-28 (DAS28) (C-Reactive Protein) Score at Week 16 for Zasocitinib Dose A and B Compared to Placebo
timeFrame: Baseline, at Week 16
measure: Change From Baseline in Physician's Global Assessment of Fingernail Psoriasis (PGA-F) Score in Participants With Psoriatic Nail Involvement (PGA-F Greater than [>] 0) From Baseline at Week 16 for Zasocitinib Dose A and B Compared to Placebo
timeFrame: Baseline, at Week 16
measure: Change From Baseline in the SF-36 v2.0 PCS Score at Week 16 for Zasocitinib Dose B Compared to Placebo
timeFrame: Baseline, at Week 16
measure: Change From Baseline in the FACIT- Fatigue Score at Week 16 for Zasocitinib Dose B Compared to Placebo
timeFrame: Baseline, at Week 16
measure: Percentage of Participants Achieving ACR50 Response at Week 16 for Zasocitinib Dose A and B Compared to Active Comparator
timeFrame: At Week 16
measure: Percentage of Participants Achieving ACR70 Response at Week 16 for Zasocitinib Dose A and B Compared to Active Comparator
timeFrame: At Week 16
measure: Percentage of Participants Achieving PASI-90 Response (in Participants With a Baseline >=3% BSA) at Week 16 for Zasocitinib Dose A and B Compared to Active Comparator
timeFrame: Baseline, at Week 16
measure: Percentage of Participants Achieving PASI-100 Response (in Participants With a Baseline >=3% BSA) at Week 16 for Zasocitinib Dose A and B Compared to Active Comparator
timeFrame: Baseline, at Week 16
measure: Percentage of Participants Achieving ACR50 and PASI-100 Response (in Participants With a Baseline >=3% BSA) Simultaneously at Week 16 for Zasocitinib Dose A and B Compared to Active Comparator
timeFrame: Baseline, at Week 16
measure: Percentage of Participants Achieving Minimal Disease Activity (MDA) at Week 16 for Zasocitinib Dose A and B Compared to Active Comparator
timeFrame: At Week 16
Other outcomes:
Locations:
city: Chandler
country: United States
facility: AARR- Chandler AZ
state: Arizona
city: Phoenix
country: United States
facility: Arizona Arthritis & Rheumatology Research, PLLC | Phoenix, AZ
state: Arizona
city: Phoenix
country: United States
facility: Arizona Arthritis & Rheumatology Research, PLLC | Phoenix, AZ
state: Arizona
city: Phoenix
country: United States
facility: Arizona Arthritis & Rheumatology Research, PLLC | Phoenix, AZ
state: Arizona
city: Fountain Valley
country: United States
facility: First OC Dermatology Research Inc.
state: California
city: La Mesa
country: United States
facility: Purushotham & Akther Kotha MD
state: California
city: La Mesa
country: United States
facility: Triwest Research Associates LLC
state: California
city: Mather
country: United States
facility: VA Northern California Health Care System - NAVREF - PPDS
state: California
city: Poway
country: United States
facility: Biosolutions Research Center | La Mesa, CA
state: California
city: Thousand Oaks
country: United States
facility: The Cohen Medical Centers
state: California
city: Tujunga
country: United States
facility: Foothill Arthritis Clinic
state: California
city: Whittier
country: United States
facility: Medvin Clinical Research
state: California
city: Denver
country: United States
facility: Denver Arthritis Clinic | Denver, CO
state: Colorado
city: Aventura
country: United States
facility: Arthritis & Rheumatic Disease Specialties (AARDS)
state: Florida
city: Boca Raton
country: United States
facility: RASF- Clinical Research Center
state: Florida
city: Clearwater
country: United States
facility: Clinical Research of West Florida | Clearwater, FL
state: Florida
city: Cooper City
country: United States
facility: GNP Research, LLC | Hollywood, FL
state: Florida
city: Coral Gables
country: United States
facility: Driven Research LLC
state: Florida
city: Davie
country: United States
facility: Tectum Medical Research
state: Florida
city: Hialeah
country: United States
facility: Sweet Hope Research Specialty, Inc, d/b/a Neoclinical Research
state: Florida
city: Miami
country: United States
facility: Bioresearch Partners
state: Florida
city: Orlando
country: United States
facility: HMD Research LLC | Orlando, FL
state: Florida
city: Ormond Beach
country: United States
facility: Millennium Research | Ormond Beach, FL
state: Florida
city: Plantation
country: United States
facility: IRIS Research and Development | Plantation, FL
state: Florida
city: Sarasota
country: United States
facility: Sarasota Arthritis Research Center
state: Florida
city: Tamarac
country: United States
facility: West Broward Rheumatology Associates, Inc.
state: Florida
city: Tampa
country: United States
facility: Clinical Research of West Florida | Tampa, FL
state: Florida
city: Marietta
country: United States
facility: Marietta Rheumatology Associates
state: Georgia
city: Orland Park
country: United States
facility: GSCP/CIS
state: Illinois
city: Schaumburg
country: United States
facility: Greater Chicago Specialty Physicians LLC/CIS
state: Illinois
city: Lake Charles
country: United States
facility: Accurate Clinical Research, Inc. | Lake Charles
state: Louisiana
city: Hagerstown
country: United States
facility: Klein & Associates, M.D., P.A.
state: Maryland
city: Detroit
country: United States
facility: Henry Ford Health System-Rheumatology Department
state: Michigan
city: Grand Blanc
country: United States
facility: Michigan Rheumatology Group, P.C. - Grand Blanc Office
state: Michigan
city: Lansing
country: United States
facility: June DO, PC Private Practice - Dr. Justus Fiechtner
state: Michigan
city: Saint Clair Shores
country: United States
facility: Clinical Research Institute of Michigan
state: Michigan
city: Saline
country: United States
facility: Ascent Urgent Care & Walk In Clinic
state: Michigan
city: Saint Louis
country: United States
facility: Saint Louis Rheumatology
state: Missouri
city: Albuquerque
country: United States
facility: Albuquerque Center for Rheumatology PC
state: New Mexico
city: Santa Fe
country: United States
facility: Santa Fe Rheumatology
state: New Mexico
city: Brooklyn
country: United States
facility: NYU Langone Health | Joseph S. and Diane H. Steinberg Ambulatory Care Center - Rheumatology Department
state: New York
city: Hickory
country: United States
facility: Accellacare of Hickory
state: North Carolina
city: Cleveland
country: United States
facility: University Hospitals | UH Cleveland Medical Center - Department of Medicine - Rheumatology Division
state: Ohio
city: Middleburg Heights
country: United States
facility: Paramount Medical Research & Consulting, LLC
state: Ohio
city: Wyomissing
country: United States
facility: PA Regional Center for Arthritis and Osteoporosis Research
state: Pennsylvania
city: Jackson
country: United States
facility: West Tennessee Research Institute
state: Tennessee
city: Baytown
country: United States
facility: Accurate Clinical Research
state: Texas
city: Houston
country: United States
facility: Novel Research | Bellaire Location
state: Texas
city: Houston
country: United States
facility: Novel Research | Bellaire Location
state: Texas
city: Houston
country: United States
facility: Accurate Clinical Research
state: Texas
city: Houston
country: United States
facility: Introscience Research | Northwest Houston Arthritis Center - Houston, TX
state: Texas
city: Lubbock
country: United States
facility: West Texas Clinical Research
state: Texas
city: Mesquite
country: United States
facility: Southwest Rheumatology Research, LLC | Mesquite, TX
state: Texas
city: Plano
country: United States
facility: Clinical Investigations of Texas
state: Texas
city: Spokane
country: United States
facility: Arthritis Northwest, PLLC | Spokane, WA
state: Washington
city: Milwaukee
country: United States
facility: Medical College of Wisconsin | Department of Medicine - Rheumatology Division
state: Wisconsin
city: Anderlecht
country: Belgium
facility: Université Libre de Bruxelles
state: Brussels
city: Gent
country: Belgium
facility: University Hospital Ghent
state: Flanders
city: Genk
country: Belgium
facility: RerumaClinic Genk
state: Limburg
city: Brussels
country: Belgium
facility: St Pierre Brussels
city: Liege
country: Belgium
facility: Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman
city: Sofia
country: Bulgaria
facility: Diagnostic Consultative Centre - Focus-5 - LZIP EOOD
state: Sofia-Grad
city: Sofia
country: Bulgaria
facility: Military Medical Academy Multiprofile Hospital for Not Yet Recruiting Treatment - Sofia
state: Sofia-Grad
city: Sofia
country: Bulgaria
facility: Centre of Rheumatology St. Irina
state: Sofia-Grad
city: Pleven
country: Bulgaria
facility: Medical Center Medconsult Pleven OOD
city: Plovdiv
country: Bulgaria
facility: AES Partner Site -Plovdiv
city: Plovdiv
country: Bulgaria
facility: Medical Center Artmed OOD | Plovdiv, Bulgaria
city: Ruse
country: Bulgaria
facility: Diagnostic- Consultative Center- 1- Ruse EOOD
city: Stara Zagora
country: Bulgaria
facility: Dr Stoyanka Vladeva IPSMP VBR | Stara Zagora, Bulgaria
city: Stara Zagora
country: Bulgaria
facility: Medical Center Zara-Med EOOD
city: Santiago
country: Chile
facility: Clinica Dermacross S.A.
state: Region Metropolitana De Santiago
city: Providencia
country: Chile
facility: El Centro de Estudios Reumatologicos (CER)
state: Santiago
city: Santiago
country: Chile
facility: Centro de Estudios Clinicos
city: Santiago
country: Chile
facility: CTR Estudios
city: Santiago
country: Chile
facility: Centro Internacional de Estudios Clínicos
city: Barranquilla
country: Colombia
facility: Centro Integral de Reumatologia Circaribe S.A.S.
state: Atlantico
city: Bogota D.C.
country: Colombia
facility: Centro de Investigacion en Reumatologia y Especialidades Medicas S.A.S, CIREEM S.A.S
state: Cundinamarca
city: Bogotá D.C.
country: Colombia
facility: Fundacion Santa Fe de Bogota
state: Cundinamarca
city: Bucaramanga
country: Colombia
facility: Servimed S.A.S
state: Cundinamarca
city: Chia
country: Colombia
facility: Preventive Care S.A.S.
state: Cundinamarca
city: Zagreb
country: Croatia
facility: Medicinski Centar Kuna and Peric
state: Grad Zagreb
city: Osijek
country: Croatia
facility: Clinical Hospital Centre Osijek
city: Rijeka
country: Croatia
facility: Clinical Hospital Center Rijeka
city: Split
country: Croatia
facility: University Hospital Centre Split
city: Zadar
country: Croatia
facility: General Hospital Zadar
city: Brno
country: Czechia
facility: Revmatologie s.r.o. | Brno, Czech Republic
state: Czech Rep
city: Hlučín
country: Czechia
facility: L.K.N. Arthrocentrum, s.r.o. - Revmatologicka
state: Czech Rep
city: Prague
country: Czechia
facility: Praglandia | Prague, Czech Republic
state: Czech Rep
city: Praha 10
country: Czechia
facility: Clintrial s.r.o. | Prague, Czech Republic
state: Czech Rep
city: Uherske Hradiste
country: Czechia
facility: MEDICAL Plus s.r.o.
state: Czech Rep
city: Ostrava
country: Czechia
facility: CCR Ostrava
state: Moravskoslezský Kraj
city: Zlin
country: Czechia
facility: Pv Medical Services
state: NAP
city: Praha 2
country: Czechia
facility: Revmatologicky ustav | Clinical Evaluation Department
state: Prague
city: Pardubice
country: Czechia
facility: Pratia Pardubice a.s.
city: Tallinn
country: Estonia
facility: Innomedica OU | Tallinn, Estonia
state: Harjumaa
city: Tallinn
country: Estonia
facility: Center for Clinical and Basic Research
state: Harjumaa
city: Tartu
country: Estonia
facility: Clinical Research Centre | Tartu, Estonia
state: Tartumaa
city: Tallinn
country: Estonia
facility: North Estonia Medical Centre | Mustamae Building - Internal Medicine Clinic - Rheumatology Department
city: Tartu
country: Estonia
facility: MediTrials OÜ
city: Bad Doberan
country: Germany
facility: Rheumzentrum Prof.Dr.med.Gunther Neeck
state: MV
city: Bad Bentheim
country: Germany
facility: Fachklinik Bad Bentheim
state: Niedersachsen
city: Ratingen
country: Germany
facility: Rheumazentrum Ratingen-Studienambulanz
state: North Rhine-Westphalia
city: Leipzig
country: Germany
facility: Universitaetsklinikum Leipzig AoeR
state: Sachsen
city: Berlin
country: Germany
facility: Rheumatologische Schwerpunktpraxis | Berlin, Germany
city: Dresden
country: Germany
facility: Städtisches Klinikum Dresden
city: Hamburg
country: Germany
facility: MVZ Rheumatologie und Autoimmunmedizin Hamburg GmbH - Hamburg
city: München
country: Germany
facility: Medicover MVZ München Ost
city: Hodmezovasarhely
country: Hungary
facility: Porcika Klinika
state: Csongrad-Csanad
city: Szeged
country: Hungary
facility: Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont
state: Csongrad-Csanad
city: Szekesfehervar
country: Hungary
facility: CMed Rehabilitacios es Diagnosztikai Kozpont
state: Fejer
city: Budapest
country: Hungary
facility: Qualiclinic | Budapest, Hungary
city: Szekesfehervar
country: Hungary
facility: Fejer Varmegyei Szent Gyorgy Egyetemi Oktató Korhaz | Rheumatology Department - Arthritis Center
city: Veszprem
country: Hungary
facility: Vital Medical Center Medical Center and Dental Center | Reumatologia - Veszprem, Hungary
city: Ashdod
country: Israel
facility: Assuta Ashdod Medical Center
state: HaDarom
city: Ashkelon
country: Israel
facility: Barzilai Medical Center | Rheumatology Department
city: Haifa
country: Israel
facility: Rambam Health Care Campus
city: Nahariya
country: Israel
facility: Galilee Medical Center | Rheumatology Unit
city: Ramat Gan
country: Israel
facility: The Chaim Sheba Medical Center - The Zabludowicz Center for Autoimmune Diseases
city: Tel Aviv
country: Israel
facility: Tel Aviv Sourasky Medical Center
city: Torrette
country: Italy
facility: Azienda Ospedaliero-Universitaria delle Marche; SOD Clinica Medica
state: Ancona
city: Roma
country: Italy
facility: Fondazione PTV Policlinico Tor Vergata
state: Lazio
city: Roma
country: Italy
facility: Policlinico Agostino Gemelli, UOC Reumatology
state: Lazio
city: Milan
country: Italy
facility: ASST Centro Specialistico Ortopedico Traumatologico Gaetano Pini-CTO
state: Lombardia
city: Milan
country: Italy
facility: Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele
state: Lombardia
city: Milan
country: Italy
facility: Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele
state: Lombardia
city: Rozzano
country: Italy
facility: IRCCS Istituto Clinico Humanitas
state: Milano
city: Padova
country: Italy
facility: Universita Degli Studi Di Padova
state: Padua
city: Firenze
country: Italy
facility: Azienda Ospedaliera Universitaria Careggi
city: Pisa
country: Italy
facility: Azienda Ospedaliero Universitaria Pisana
city: Suwon-si
country: Korea, Republic of
facility: The Catholic University of Korea
state: Gyeonggi-do
city: Suwon-si
country: Korea, Republic of
facility: Ajou University Hospital | Clinical Trial Center
state: Gyeonggido
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
city: Seoul
country: Korea, Republic of
facility: SMG - SNU Boramae Medical Center
city: Seoul
country: Korea, Republic of
facility: Kyung Hee University Hospital
city: Liepaja
country: Latvia
facility: D. Saulites Kandevicas Private Practice in Cardiology and Rheumatology | Liepaja, Latvia
city: Riga
country: Latvia
facility: ORTO Clinic | Rheumatology Department
city: Mexicali
country: Mexico
facility: Centro de Investigacion en Artritis y Osteoporosis S.C. (CIAO)
state: Baja California
city: Ciudad de Mexico
country: Mexico
facility: HMG Hospital Coyoacan
state: Cdmx
city: Gustavo A. Madero
country: Mexico
facility: Consultorio de Reumatologia
state: Distrito Federal
city: Mexico
country: Mexico
facility: CINTRE, Centro de Investigacion y Tratamiento Reumatologico S.C.
state: Distrito Federal
city: Zapopan
country: Mexico
facility: iBiomed Guadalajara
state: Guadalajara
city: Guadalajara
country: Mexico
facility: Centro Integral en Reumatologia, S.A. de C.V.
state: Jalisco
city: Guadalajara
country: Mexico
facility: Private Practice - Dr. Delfina Villanueva Quintero
state: Jalisco
city: Merida
country: Mexico
facility: Kohler and Milstein Research Yucatan
state: Yucatan
city: Merida
country: Mexico
facility: Hospitales Star Medica
state: Yucatan
city: Chihuahua
country: Mexico
facility: Office of Cesar F. Pacheco-Tena, MD
city: Christchurch Central
country: New Zealand
facility: CGM Research Trust
state: Christchurch
city: Auckland
country: New Zealand
facility: Aotearoa Clinical Trials
state: North Island
city: Auckland
country: New Zealand
facility: North Shore Hospital
state: North Island
city: Nelson
country: New Zealand
facility: Porter Rheumatology Ltd
state: South Island
city: Hamilton
country: New Zealand
facility: Waikato Hospital
state: Waikato
city: Katowice
country: Poland
facility: Centrum Medyczne Katowice - PRATIA
state: Dolnoslaskie
city: Wroclaw
country: Poland
facility: WroMedica Centrum Zdrowia | Rheumatology Clinic
state: Dolnoslaskie
city: Krakow
country: Poland
facility: Pratia MCM Krakow
state: Malopolskie
city: Krakow
country: Poland
facility: Krakowskie Centrum Medyczne
state: Malopolskie
city: Kraków
country: Poland
facility: Centrum Medyczne Plejady
state: Malopolskie
city: Sochaczew
country: Poland
facility: RCMed | Sochaczew, Poland
state: Mazowieckie
city: Warsaw
country: Poland
facility: Klinika Reuma Park
state: Mazowieckie
city: Warszawa
country: Poland
facility: Rheuma Medicus | Warsaw, Poland
state: Mazowieckie
city: Warszawa
country: Poland
facility: MTZ Clinical Research Powered by PRATIA
state: Mazowieckie
city: Warszawa
country: Poland
facility: Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji im. prof. dr hab. med. Eleonory Reicher, Centrum Wsparcia Badań Klinic
state: Mazowieckie
city: Warszawa
country: Poland
facility: ETG Warszawa
state: Mazowieckie
city: Opole
country: Poland
facility: Twoja Przychodnia | Opole, Poland
state: Opolskie
city: Bialystok
country: Poland
facility: INTER CLINIC Piotr Adrian Klimiuk | Bialystok, Poland
state: Podlaskie
city: Bialystok
country: Poland
facility: Nova Reuma Domyslawska i Rusilowicz- Spolka Partnerska Lekarza Reumatologa i Fizjoterapeuty
state: Podlaskie
city: Bialystok
country: Poland
facility: Zdrowie Osteo Medic sc L i A Racewicz, A i J Supronik
state: Podlaskie
city: Torun
country: Poland
facility: MICS Centrum Medyczne Torun
state: Silesia
city: Olsztyn
country: Poland
facility: Etyka Osrodek Badan Klinicznych | Olsztyn, Poland
state: Warmia-Masuria
city: Dabrowka
country: Poland
facility: UNICA CR sp. z.o. o.
state: Warmian-Masurian Voivodeship
city: Elbląg
country: Poland
facility: Ambulatorium Sp. z o.o.
state: Warminsko-Mazurskie
city: Poznan
country: Poland
facility: Twoja Przychodnia - Poznanskie Centrum Medyczne Sp. z o.o.
state: Wielkopolska
city: Poznan
country: Poland
facility: Reumedika | Poznan, Poland
state: Wlkp
city: Poznan
country: Poland
facility: Prywatna Praktyka Lekarska Prof. dr hab. med. Pawel Hrycaj | Poznan, Poland
state: Woj. Wielkopolskie
city: Poznan
country: Poland
facility: Pratia Poznań
state: Wojewodztwo Wielkopolskie
city: Nowa Sól
country: Poland
facility: Twoja Przychodnia | Nowa Sol, Poland
city: Wrocław
country: Poland
facility: FutureMeds Wroclaw
city: Łódź
country: Poland
facility: Santa Familia PTG Lodz | Lodz, Poland
city: Łódź
country: Poland
facility: FutureMeds | Lodz Center - Lodz, Poland
city: Bytom
country: Poland
facility: Bif-Med s.c. NZOZ
state: Śląskie
city: Coimbra
country: Portugal
facility: Centro Hospitalar e Universitário de Coimbra E.P.E - Hospitais da Universidade de Coimbra
state: Barcelona
city: Ponte de Lima
country: Portugal
facility: Hospital Conde de Bertiandos Unidade Local de Saúde Do Alto Minho
state: Barcelona
city: Vila Nova de Gaia
country: Portugal
facility: Centro Hospitalar de Vila Nova de Gaia / Espinho E.P.E
state: New Mexico
city: Almada
country: Portugal
facility: Hospital Garcia de Orta
city: Coimbra
country: Portugal
facility: Centro Hospitalar e Universitário de Coimbra E.P.E - Hospitais da Universidade de Coimbra
city: Lisboa
country: Portugal
facility: Instituto Portugues de Reumatologia
city: Lisboa
country: Portugal
facility: Centro Hospitalar Universitario de Lisboa Norte | Hospital Santa Maria - Rheumatology Department
city: Caguas
country: Puerto Rico
facility: Centro Reumatologico de Caguas | Caguas, PR
city: San Juan
country: Puerto Rico
facility: GCM Medical Group, PSC | San Juan, PR
city: Merida
country: Spain
facility: Hospital Universitario de Badajoz
state: Badajoz
city: Sabadell
country: Spain
facility: Corporacio Sanitaria Parc Tauli - Hospital de Sabadell
state: Barcelona
city: Santiago de Compostela
country: Spain
facility: Hospital Clinico Universitario de Santiago de Compostela | Building A - Rheumatology Department
state: Galicia
city: Malaga
country: Spain
facility: Hospital Regional Universitario de Malaga
city: Sevilla
country: Spain
facility: Hospital Universitario Virgen Macarena
city: Valencia
country: Spain
facility: Hospital Clinico Universitario de Valencia
city: Tainan
country: Taiwan
facility: National Cheng Kung University
state: Tainan City
city: Zhong Zheng Qu
country: Taiwan
facility: National Taiwan University Hospital
state: Taipei City
city: New Taipei City
country: Taiwan
facility: Far Eastern Memorial Hospital | Allergy, Immunology and Rheumatology Department
city: Taichung
country: Taiwan
facility: Chung Shan Medical University Hospital
city: Tainan City
country: Taiwan
facility: Chi Mei Medical Center
Study officials:
affiliation: Takeda
name: Study Director
role: STUDY_DIRECTOR
References: